A Study to Evaluate Safety, Tolerability, and Antiviral Activity of BRII-179 (VBI-2601) amongSubjects with Chronic Hepatitis B
Phase 1
Completed
- Conditions
- Chronic Hepatitis B virus (HBV) infectionInfection - Other infectious diseasesOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
- Registration Number
- ACTRN12619001210167
- Lead Sponsor
- Brii Biosciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 49
Inclusion Criteria
1) Male or female age 18 to 60
2) BMI 18 to 32 kg per meter 2
3) Chronic HBV infection for greater than or equal 6 months
Exclusion Criteria
1) Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation
2) Significant fibrosis or cirrhosis
3) History or evidence of drug or alcohol abuse
4) History of intolerance to intramuscular injection
5) History of chronic liver disease from any cause other than chronic HBV infection
6) History of hepatic decompensation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method